NORTH AMERICA CARDIOVASCULAR ULTRASOUND MARKET FORECAST 2026-2034

Technological tailwinds, including AI-powered imaging platforms and the rise of handheld echocardiography, are further expanding clinical access and driving equipment refresh cycles among hospitals and ambulatory care centers alike. These factors, taken together, are set to boost the North America cardiovascular ultrasound market growth throughout the forecast period.

The North America cardiovascular ultrasound market growth assessment includes the analysis of the United States and Canada.

The United States stands at the epicenter of the North American cardiac ultrasound systems market, driven by the highest cardiovascular disease burden in the region and a healthcare system that is among the most advanced in the world. As per the CDC, heart disease remains the leading cause of death for men, women, and most racial and ethnic groups in the United States, with one person dying from cardiovascular disease every 34 seconds.

This clinical urgency creates relentless demand for cardiac diagnostic procedures, including the transthoracic echocardiogram, which alone accounts for over half of cardiovascular ultrasound procedure volumes nationally. The U.S. also benefits from a dense concentration of leading cardiac ultrasound manufacturers, active R&D pipelines, and rapid clinical adoption of advanced modalities such as 3D and 4D echocardiography and AI-assisted imaging. GE HealthCare, Siemens Healthineers, and Philips all maintain strong commercial presences in the country, continuously launching upgraded systems and competing on the basis of AI integration, workflow efficiency, and connectivity.

Regulatory and reimbursement dynamics play a particularly significant role in shaping the U.S. cardiac ultrasound machine price landscape and overall market behavior. CMS sets reimbursement rates for echocardiography under the Medicare Physician Fee Schedule, and as the American Society of Echocardiography has noted, these rates have faced persistent downward pressure due to Medicare’s statutory budget-neutrality requirements.

As more patients enter the Medicare system, driven by an aging population, CMS is required to distribute payments across a growing number of procedures, effectively reducing per-procedure reimbursements over time. This creates a challenging operating environment for cardiology practices and imaging centers, particularly smaller, independent providers, who may struggle to justify the cardiac ultrasound cost of premium system upgrades. Nevertheless, the sheer scale of demand, the prevalence of private insurance, and the growing emphasis on value-based cardiac care continue to position the United States as the largest and most strategically important market for cardiovascular ultrasound globally.

In Canada, the cardiovascular ultrasound market is underpinned by a persistent and growing disease burden, supported by a publicly funded healthcare system that prioritizes non-invasive cardiac diagnostic procedures. According to the Canadian Chronic Disease Surveillance System (CCDSS) data, approximately 2.6 million Canadian adults aged 20 and over live with diagnosed heart disease, roughly 1 in 12 adults.

Heart disease is the second leading cause of death in Canada, as noted by Statistics Canada, and cardiovascular disease as a whole accounts for an estimated $21.2 billion in direct and indirect costs annually, according to the Heart and Stroke Foundation of Canada. Moreover, approximately 25% of Canadian adults aged 20 and older are living with diagnosed hypertension, a major driver of follow-up echocardiographic screening and monitoring.

Canada’s universal healthcare framework provides a baseline of cardiac imaging access, and provincial health authorities are increasingly investing in advanced cardiovascular imaging equipment to address growing wait times and cardiac care demands. While reimbursement constraints and regional disparities in healthcare access present challenges, Canada’s aging population and sustained government investment in healthcare infrastructure continue to support steady demand growth for cardiovascular ultrasound across hospitals and diagnostic centers.

The North America cardiovascular ultrasound market is segmented by device display, technology, application, type, and end-user. The device display segment is further categorized into color display systems and black & white (B/W) display systems.

Color display systems dominate the device display segment across North America, and this dominance is well-supported by the clinical realities of cardiovascular imaging. These systems integrate color Doppler technology, which allows clinicians to visualize blood flow direction, velocity, and turbulence within the heart in real time. These capabilities are indispensable for diagnosing valvular disease, detecting intracardiac shunts, and assessing hemodynamic function.

In a region where cardiac diagnostic procedures are routinely performed across high-volume hospital echo labs, diagnostic centers, and ambulatory care centers, the demand for systems that deliver both structural imaging and flow data on a single platform is exceptionally high. Color display systems also align well with the growing adoption of AI-enhanced cardiovascular ultrasound in North America, as advanced color overlay features and AI-driven tissue classification tools are almost exclusively developed for color-capable platforms.

Some of the top players operating in the North America cardiovascular ultrasound market include GE HealthCare, Koninklijke Philips NV, Siemens Healthineers AG, Mindray Medical International Limited, etc.

GE HealthCare is a U.S.-headquartered global medical technology company operating at the intersection of advanced cardiovascular imaging and digital health. In the cardiac ultrasound systems market, GE HealthCare offers a broad portfolio ranging from premium cart-based systems, including the Vivid cardiovascular ultrasound series, to portable and handheld platforms such as the Vscan Air SL, which features Caption AI for automated left ventricular ejection fraction (LVEF) measurement. Its deep integration of AI across cardiac imaging workflows, combined with its global service network and consistent investment of over $1 billion annually in imaging research, positions GE HealthCare as the most comprehensively resourced player in the North American cardiovascular ultrasound market.